Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,772 across all filing types
Latest filing 2025-08-27 Director's Dealing
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec SE: Dr. Christian Wojczewski, buy
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction in shares by a person discharging managerial responsibilities (Dr. Christian Wojczewski, a member of the managing body of Evotec SE). It explicitly follows the regulatory disclosure format for 'Directors' Dealings' (insider trading notification), detailing the nature of the transaction (acquisition), price, volume, and date. This aligns perfectly with the definition for the 'DIRS' category.
2025-08-27 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a formal notification of major holdings (voting rights) filed by BlackRock, Inc. regarding its interest in Evotec SE. It explicitly references 'Article 40, Section 1 of the WpHG' (German Securities Trading Act) and provides detailed tables of voting rights and controlled undertakings. This fits the definition of a 'Major Shareholding Notification' (MRQ) as it details changes in significant share ownership levels crossing regulatory thresholds.
2025-08-20 English
Evotec SE reports H1 2025 results: Strong progress on strategy execution
Earnings Release Classification · 1% confidence The document is a corporate news release announcing the H1 2025 financial results for Evotec SE. It provides key highlights, management commentary, and guidance, while explicitly directing readers to a separate link on the company's website to access the full half-year report. As it is an announcement of financial results rather than the full report itself, and it follows the standard format for an earnings release, it is classified as an Earnings Release (ER). H1 2025
2025-08-13 English
Half-yearly financial report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM STATEMENT 6M 2025' and provides a comprehensive financial review for the first six months of the fiscal year. It includes detailed consolidated income statements, segment information (Discovery & Preclinical Development and Just – Evotec Biologics), and a 'Report on the Financial Situation and Results' section. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-13 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a formal notification of major holdings (voting rights) filed by BlackRock, Inc. regarding its interest in Evotec SE. It explicitly references 'Article 40, Section 1 of the WpHG' (German Securities Trading Act) and provides detailed tables on voting rights, instruments, and the chain of controlled undertakings. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-08-11 English
Evotec SE to announce first half-year results 2025 on 13 August 2025
Report Publication Announcement Classification · 1% confidence The document is a corporate announcement from Evotec SE informing the public and investors about the upcoming release of their half-year interim report on 13 August 2025. It provides details regarding the date, time, and registration links for the associated conference call and webcast. Per the 'Menu vs Meal' rule, this is an announcement of a future report rather than the report itself, making it a Report Publication Announcement (RPA).
2025-08-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.